Hepatitis B virus surface antigen activates myeloid dendritic cells via a soluble CD14-dependent mechanism

Journal of Virology

Volumn 90, Issue 14, 2016, Pages 6187-6199

  Montfoort, Nadine Van ^a,c   Aa, Evelyn van der ^a   Bosch, Aniek van den ^a   Brouwers, Hilde ^a   Vanwolleghem, Thomas ^a   Janssen, Harry L A ^a,d   Javanbakht, Hassan ^b   Buschow, Sonja I ^a   Woltman, Andrea M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; TOLL LIKE RECEPTOR 4; CD1 ANTIGEN; CD1C PROTEIN, HUMAN; GLYCOPROTEIN; TLR4 PROTEIN, HUMAN;

ARTICLE; CELL ACTIVATION; CELL MATURATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; MYELOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ADOLESCENT; ADULT; AGED; BONE MARROW CELL; CHRONIC HEPATITIS B; CYTOLOGY; DENDRITIC CELL; FEMALE; FETUS BLOOD; HEPATITIS B VIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD1; ANTIGENS, CD14; DENDRITIC CELLS; FEMALE; FETAL BLOOD; GLYCOPROTEINS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELOID CELLS; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 4; YOUNG ADULT;

EID: 84977476181     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02903-15     Document Type: Article

References (40)

1. Yim HJ, Lok AS-F. 2006. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43:S173-S181. http://dx.doi.org/10.1002/hep.20956.
2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. 2015. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386: 1546-1555. http://dx.doi.org/10.1016/S0140-6736(15)61412-X.
3. Bertoletti A, Ferrari C. 2012. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61:1754-1764. http://dx.doi.org/10.1136/gutjnl-2011-301073.
4. van Montfoort N, van der Aa E, Woltman AM. 2014. Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines. Front Immunol 5:182. http://dx.doi.org/10.3389/fimmu.2014.00182.
5. Dalod M, Chelbi R, Malissen B, Lawrence T. 2014. Dendritic cell maturation functional specialization through signaling specificity and transcriptional programming. EMBO J 33:1104-1116. http://dx.doi.org/10.1002/embj.201488027.
6. Op den Brouw ML, Binda RS, Geijtenbeek TBH, Janssen HLA, Woltman AM. 2009. The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. Virology 393:84-90. http://dx.doi.org/10.1016/j.virol.2009.07.015.
7. Untergasser A, Zedler U, Langenkamp A, Hösel M, Quasdorff M, Esser K, Dienes H-P, Tappertzhofen B, Kolanus W, Protzer U. 2006. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43:539-547. http://dx.doi.org/10.1002/hep.21048.
8. Woltman AM, Boonstra A, Janssen HLA. 2010. Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels? Gut 59:115-125. http: //dx.doi.org/10.1136/gut.2009.181040.
9. Boltjes A, Groothuismink ZM, van Oord GW, Janssen HLA, Woltman AM, Boonstra A. 2014. Monocytes from chronic HBV patients react in vitro to HBsAg and TLR by producing cytokines irrespective of stage of disease. PLoS One 9:e97006. http://dx.doi.org/10.1371/journal.pone.0097006.
10. Jan R-H, Lin Y-L, Chen C-J, Lin T-Y, Hsu Y-C, Chen L-K, Chiang B-L. Hepatitis B virus surface antigen can activate human monocytederived dendritic cells by nuclear factor kappa B and p38 mitogenactivated protein kinase mediated signaling. Microbiol Immunol 56:719-727. http://dx.doi.org/10.1111/j.1348-0421.2012.00496.x.
11. Boltjes A, van Montfoort N, Biesta PJ, Op den Brouw ML, Kwekkeboom J, van der Laan LJW, Janssen HLA, Boonstra A, Woltman AM. Kupffer cells interact with HBsAg in vivo and in vitro leading to pro-inflammatory cytokine production and NK cell function. J Infect Dis 211:1268-1278. http://dx.doi.org/10.1093/infdis/jiu599.
12. Schwarz H, Schmittner M, Duschl A, Horejs-Hoeck J. 2014. Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells. PLoS One 9:e0113840. http://dx.doi.org/10.1371/journal.pone.0113840.
13. Gao B, Wang Y, Tsan M-F. 2006. The heat sensitivity of cytokineinducing effect of lipopolysaccharide. J Leukoc Biol 80:359-366. http://dx.doi.org/10.1189/jlb.1205738.
14. Desombere I, Willems A, Gijbels Y, Leroux-Roels G. 2006. Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen. J Virol 80:3506-3514. http://dx.doi.org/10.1128/JVI.80.7.3506-3514.2006.
15. Gehring AJ, Xue S-A, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A. 2011. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 55:103-110. http://dx.doi.org/10.1016/j.jhep.2010.10.025.
16. Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, Wasan PS, Wang X-N, Malinarich F, Malleret B, Larbi A, Tan P, Zhao H, Poidinger M, Pagan S, Cookson S, Dickinson R, Dimmick I, Jarrett RF, Renia L, Tam J, Song C, Connolly J, Chan JKY, Gehring A, Bertoletti A, Collin M, Ginhoux F. 2012. Human tissues contain CD141(hi) crosspresenting dendritic cells with functional homology to mouse CD103(+) nonlymphoid dendritic cells. Immunity 37:60-73. http://dx.doi.org/10.1016/j.immuni.2012.04.012.
17. Heijtink RA, Kruining J, Weber YA, de Man RA, Schalm SW. 1995. Anti-hepatitis B virus activity of a mixture of two monoclonal antibodies in an "inhibition in solution" assay. Hepatology 22:1078-1083. http://dx.doi.org/10.1002/hep.1840220410.
18. Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus ADME, Pas SD, Janssen HLA, Boonstra A. 2015. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology 62:87-100. http://dx.doi.org/10.1002/hep.27805.
19. Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Stelter F, Peterson DL, Gomez-Gutierrez J, Gavilanes F, Leroux-Roels G. 2002. LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles. J Gen Virol 83:2279-2289. http://dx.doi.org/10.1099/0022-1317-83-9-2279.
20. Zanoni I, Granucci F. 2013. Role of CD14 in host protection against infections and in metabolism regulation. Front Cell Infect Microbiol 3:32. http://dx.doi.org/10.3389/fcimb.2013.00032.
21. Yang Z, Breider MA, Carroll RC, Miller MS, Bochsler PN. 1996. Soluble CD14 and lipopolysaccharide-binding protein from bovine serum enable bacterial lipopolysaccharide-mediated cytotoxicity and activation of bovine vascular endothelial cells in vitro. J Leukoc Biol 59:241-247.
22. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavaillon N, Goldman M. 1997. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14- dependent pathway. J Immunol 158:2919-2925.
23. LeVan TD, Guerra S, Klimecki W, Vasquez MM, Lohman IC, Martinez FD, Halonen M, Wright AL. 2006. The impact of CD14 polymorphisms on the development of soluble CD14 levels during infancy. Genes Immun 7:77-80. http://dx.doi.org/10.1038/sj.gene.6364276.
24. Gehring AJ, Ann D'Angelo J. 2015. Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cell Mol Immunol 12:283-291. http://dx.doi.org/10.1038/cmi.2014.95.
25. Tjwa ETTL, van Oord GW, Biesta PJ, Boonstra A, Janssen HLA, Woltman AM. 2012. Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection. J Virol 86:4102-4109. http://dx.doi.org/10.1128/JVI.07000-11.
26. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1:398-401. http://dx.doi.org/10.1038/80833.
27. Nazli A, Kafka JK, Ferreira VH, Anipindi V, Mueller K, Osborne BJ, Dizzell S, Chauvin S, Mian MF, Ouellet M, Tremblay MJ, Mossman KL, Ashkar AA, Kovacs C, Bowdish DME, Snider DP, Kaul R, Kaushic C. HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium. J Immunol 191:4246-4258. http://dx.doi.org/10.4049/jimmunol.1301482.
28. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. 1994. CD14 is a pattern recognition receptor. Immunity 1:509-516. http://dx.doi.org/10.1016/1074-7613(94)90093-0.
29. Zanoni I, Ostuni R, Capuano G, Collini M, Caccia M, Ronchi AE, Rocchetti M, Mingozzi F, Foti M, Chirico G, Costa B, Zaza A, Ricciardi- Castagnoli P, Granucci F. 2009. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature 460:264-268. http://dx.doi.org/10.1038/nature08118.
30. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HLA. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One 6:e15324. http://dx.doi.org/10.1371/journal.pone.0015324.
31. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen C-JJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJE, Hart DNJ, Radford KJ. 2010. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 207:1247-1260. http://dx.doi.org/10.1084/jem.20092140.
32. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, de Vries IJ. 2010. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 59:1573-1582. http://dx.doi.org/10.1007/s00262-010-0833-1.
33. Paik Y-H, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37:1043-1055. http://dx.doi.org/10.1053/jhep.2003.50182.
34. Bazil V, Strominger JL. 1991. Shedding as a mechanism of downmodulation of CD14 on stimulated human monocytes. J Immunol 147: 1567-1574.
35. Landmann R, Fisscher AE, Obrecht JP. 1992. Interferon-gamma and interleukin-4 down-regulate soluble CD14 release in human monocytes and macrophages. J Leukoc Biol 52:323-330.
36. Pan Z, Zhou L, Hetherington CJ, Zhang DE. 2000. Hepatocytes contribute to soluble CD14 production, and CD14 expression is differentially regulated in hepatocytes and monocytes. J Biol Chem 275:36430-36435. http://dx.doi.org/10.1074/jbc.M003192200.
37. Su GL, Dorko K, Strom SC, Nüssler AK, Wang SC. 1999. CD14 expression and production by human hepatocytes. J Hepatol 31:435-442. http://dx.doi.org/10.1016/S0168-8278(99)80034-8.
38. Berner R, Fürll B, Stelter F, Dröse J, Müller H-P, Schütt C. 2002. Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis. Clin Diagn Lab Immunol 9:440-445.
39. Ni Y-H. 2011. Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol 46:1- 8. http://dx.doi.org/10.1007/s00535-010-0304-7.
40. Hong M, Sandalova E, Low D, Gehring AJ, Fieni S, Amadei B, Urbani S, Chong Y-S, Guccione E, Bertoletti A. 2015. Trained immunity in newborn infants of HBV-infected mothers. Nat Commun 6:6588. http://dx.doi.org/10.1038/ncomms7588.